Fresenius Medical Care Q3 2026 Results: Net Income $225M, Down 31.3% YoY
Fresenius Medical Care AG reported its interim financial results for the third quarter of 2026, highlighting a reorganization of its pharmaceutical business from the Care Enablement segment to the Care Delivery segment. The report also notes the integration of administrative functions for the Value-Based Care segment into global functional areas and the ongoing implementation of a new enterprise resource planning software.
- Key figure
- Net income $225M · -31.3% YoY